Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Neurocrine Biosciences
NBIX
$16.5B
| $181M | 0.16% |
1,484,764
+765,382
| +106% | +$84.6M |
|
127
Charles River Laboratories
CRL
$13.5B
| $180M | 0.16% |
1,034,779
-302,609
| -23% | -$48.3M |
|
128
AstraZeneca
AZN
$246B
| $179M | 0.15% |
1,694,978
-197,475
| -10% | -$20.4M |
|
|
WCN
129
Waste Connections
WCN
$42B
| $176M | 0.15% |
1,875,036
-140,800
| -7% | -$12.5M |
|
130
Markel Group
MKL
$22.8B
| $175M | 0.15% |
189,351
-21,220
| -10% | -$19.3M |
|
131
Dollar General
DG
$26.5B
| $173M | 0.15% |
910,497
-252,303
| -22% | -$45.7M |
|
132
Estee Lauder
EL
$31.8B
| $171M | 0.15% |
907,030
+352,100
| +63% | +$62.9M |
|
133
Aon
AON
$75.6B
| $170M | 0.15% |
884,701
+692,500
| +360% | +$129M |
|
134
National Beverage
FIZZ
$2.89B
| $170M | 0.15% |
5,580,742
+286,150
| +5% | +$7.72M |
|
135
Zoetis
ZTS
$31.1B
| $169M | 0.15% |
1,235,216
-412,362
| -25% | -$53.8M |
|
136
Logitech
LOGI
$14.8B
| $167M | 0.14% |
2,561,444
+7,542
| +0.3% | +$402K |
|
137
Pinnacle West Capital
PNW
$12.1B
| $166M | 0.14% |
2,271,686
-981,200
| -30% | -$74.1M |
|
|
ZNGA
138
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $166M | 0.14% |
17,348,900
+177,900
| +1% | +$1.46M |
|
139
Tencent Music
TME
$14.3B
| $165M | 0.14% |
12,248,400
+9,559,300
| +355% | +$113M |
|
140
Rogers Communications
RCI
$19.1B
| $162M | 0.14% |
4,043,183
+551,800
| +16% | +$23M |
|
|
TIF
141
DELISTED
Tiffany & Co.
TIF
| $162M | 0.14% |
1,330,202
+813,812
| +158% | +$102M |
|
142
Intel
INTC
$493B
| $162M | 0.14% |
2,709,594
+1,113,300
| +70% | +$66.6M |
|
143
Wheaton Precious Metals
WPM
$61B
| $160M | 0.14% |
3,629,545
+395,421
| +12% | +$15.6M |
|
144
Pan American Silver
PAAS
$21.8B
| $158M | 0.14% |
5,203,609
-2,389,295
| -31% | -$56.7M |
|
145
Scotiabank
BNS
$108B
| $156M | 0.13% |
3,788,800
+358,900
| +10% | +$14.3M |
|
146
Twilio
TWLO
$39.3B
| $156M | 0.13% |
710,595
+657,800
| +1,246% | +$106M |
|
147
CME Group
CME
$93.2B
| $153M | 0.13% |
939,418
-856,811
| -48% | -$154M |
|
|
OPTU
148
Optimum Communications Inc
OPTU
$225M
| $152M | 0.13% |
6,727,209
-1,682,491
| -20% | -$41.3M |
|
149
Bausch Health
BHC
$2.33B
| $151M | 0.13% |
8,281,249
-5,121,100
| -38% | -$90.2M |
|
150
Chunghwa Telecom
CHT
$32.9B
| $151M | 0.13% |
3,844,860
+415,289
| +12% | +$15.4M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.